Evidence Hub

Combined chemotherapy of the metastases of testicular teratoblastomas

Orel NF

Voprosy onkologii, 1979

8 participants

Abstract

Sixty two patients with metastases of testicular teratoblastoma were subjected to combination chemotherapy. Forty nine patients were treated with an association of bleomycin and vincaalkaloids. An objective effect was gained in 77.5%. Ten patients were treated with a combination of bleomycin, vinblastine, natulane, dactinomycin, an effect being gained in 60% of the patients. The treatment with cis-diamini-dichloroplatinum was effective in 8 of 11 patients (72.7%). In 6 of 10 patients treated with olivomycin and cyclophosphane the effect was obtained (in 60%), when they were resistant to bleomycin combinations. Evidence is presented of high-effectiveness of the combinations including bleomycin as well as of the effect of cis-diamini-dichloroplatinum in treatment of testicular teratoblastomas. With pharmaceutical resistance to bleomycin it is recommended to continue olivomycin and cyclophosphane chemotherapy.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 8 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free